{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-218879","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.902836+00:00","generated_at":"2026-05-31T04:55:28.163685+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure","bullets":["Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.","Termination linked to planned merger with OnKure, Inc. and cessation of drug development.","Hall will receive severance benefits under previously disclosed severance plan.","Merger with OnKure is expected to shift company away from historical drug development.","Gregory J. Flesher remains CEO; no replacement for CDO announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-218879","json":"https://secwatch.observer/filing/0001193125-24-218879.json","markdown":"https://secwatch.observer/filing/0001193125-24-218879.md","text":"https://secwatch.observer/filing/0001193125-24-218879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524218879/0001193125-24-218879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524218879/d809509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:55:28.163685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e640771d75","claim":"Ashley F. Hall was terminated as Chief Development Officer at OnKure Therapeutics, Inc..","evidence_excerpt":"the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524218879/0001193125-24-218879-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Development Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}